A patient with advanced hepatocellular carcinoma with portal vein thrombosis, who was sentenced to death by several hospitals, has been discharged from the hospital and returned to the Mongolian steppe after careful treatment by the hepatobiliary and interventional staffs of the Department of Hepatobiliary Medicine of the 309th Hospital. The patient was a 49-year-old male with a history of hepatitis B for many years. Because of “abdominal pain for half a month with weight loss”, CT examination at the local municipal people’s hospital showed a huge mass in the right lobe of the patient’s liver, with enhancement scanning showing fast-in-fast-out enhancement, and filling defects in the portal vein trunk and the left branch. Preliminary diagnosis was primary liver cancer with portal vein thrombosis. The patient came all the way to Beijing, and all the hospitals he visited told the patient and his family that the survival period of the patient would not be more than 3 months, which was tantamount to being sentenced to “death”. However, this “death sentence” is not empty. Hepatocellular carcinoma is the “king of cancers”, and when the tumor grows to a certain extent, it is easy to invade portal vein and form portal vein thrombus. When the tumor grows to a certain level, it will easily invade the portal vein and form portal vein thrombus. 60% to 90% of patients with advanced hepatocellular carcinoma have portal vein thrombus formation. Portal vein thrombus is the most important factor leading to intrahepatic spread of hepatocellular carcinoma, distant metastasis, deterioration of liver function and postoperative recurrence. Cancer thrombus not only has a high incidence rate, but also has a low surgical resection rate and a high postoperative recurrence rate. Once a portal vein thrombus is detected, doctors usually advise patients to give up the treatment. Many experts and professors who have been engaged in the treatment of liver cancer all their life are “discouraged” and “sighing at the sight of cancer”. At present, it is recognized that hepatic artery embolization chemotherapy has certain curative effect on portal vein thrombosis, but the effect is not ideal, and the survival rate is only 2.5% in 3 years after treatment. Therefore, it is crucial to carry out local treatment of portal vein to clear the thrombus to improve the treatment effect of advanced hepatocellular carcinoma and reduce the further spread of tumor cells through portal vein, so as to improve the survival rate and quality of life of hepatocellular carcinoma patients! All the medical and nursing staff of Department of Hepatobiliary and Biliary Medicine were determined to break through the “mine field” of portal vein thrombosis! After the patient was admitted to the hospital, Director Li Hucheng led Huang Hui, Wang Ruiguan, Wu Tiantian, and Zhang Wei to check the information and consult with Director Ao Guokun of Interventional Medicine Department repeatedly, and through 320-row CT, they realized that the portal vein and its left branch were completely blocked and the whole liver had low blood flow perfusion. Through the Internet and their classmates and peers studying abroad, they learned that Prof. Habbib of Imperial University of London had just invented a radiofrequency ablation catheter for portal vein thrombosis, which had just begun to be applied to the treatment of portal vein thrombosis in the United Kingdom, and the results were good after several cases of treatment in human beings. This technology places a radiofrequency catheter into the “target site” of portal vein thrombus for radiofrequency ablation, which can eliminate the occlusion of portal vein caused by tumor growth and erosion in a short period of time, effectively controlling the growth of the tumor, improving the quality of patients’ life and prolonging the survival period. The clinical application of this technology in China has not yet been reported in the literature, and only Sun Yat-sen Hospital in Guangzhou has implemented three cases of this treatment under the guidance of the Imperial University of London. They immediately contacted Prof. Habbib to discuss the treatment, and Prof. Habbib generously and selflessly passed on the treatment method and parameters to Director Li Hucheng, and quickly transferred the radiofrequency ablation catheter from Hong Kong. The support of the world’s most advanced technology and equipment increased the confidence and courage of the Department of Hepatobiliary and Gallbladder Medicine to gnaw this “hard bone”. For the Department of Hepatobiliary and Biliary Medicine and the Department of Interventional Medicine, this is another unprecedented challenge. 309 Hospital will carry out the first case of radiofrequency ablation of portal vein cancer thrombus in the whole army and Beijing. Director Ao Guokun personally operated the procedure. After successful percutaneous transhepatic puncture of the portal vein, imaging showed that the portal vein trunk and the left branch of the portal vein were completely blocked, and the blood flow completely disappeared. Under the guidance of guidewire, 5F tube sheath was inserted, RF ablation catheter was placed in the “target position” of the cancerous thrombus, and the treatment parameters were constantly adjusted and mapped out, and the cancerous thrombus of the portal trunk and the left branch of the portal vein were ablated from the bottom up under the supervision of DSA, and then the portal vein was dilated with 12mm DEEP balloon, and the imaging showed that the portal venous flow had been restored 8 hours after the operation. After the treatment, the imaging showed that the portal vein blood flow had been restored, the patient ate and got out of bed 8 hours after the operation, and the 320-row CT three days later showed that the blood flow of the portal vein and the left branch had been restored, and the perfusion of the whole liver had significantly improved, and the patient resumed normal life and went home to recuperate 7 days after the operation. The successful implementation of this new technology is another concrete practice of 309 Hospital to “strengthen the connotation” and “build a first-class general hospital for large military units” under the correct leadership of the Party Committee of the hospital. It is also a model of cooperation between departments, complementing each other’s strengths and advancing side by side. At the National Conference on Interventional Therapy for Tumors in September, Director Ao Guokun made a conference report on the case, which aroused great interest from the participants and they asked for advice on the treatment method and parameters of the treatment. Facts have proved that as long as we aim at the frontier, explore bravely and make unremitting efforts, we can walk in the forefront of the whole army, the city and even the country and break a new path.